Reported 5 days ago
Pfizer has faced a significant downturn since 2022, with its stock down 56% and revenue from its COVID-19 products dropping sharply due to new U.S. regulations limiting vaccine recommendations. Despite a possible boost from its oncology division and cost-cutting measures, the company's financial outlook remains uncertain as it grapples with these challenges, leading analysts to suggest caution for investors.
Source: YAHOO